semaglutide launch Hyderabad-based Natco Pharma Ltd. has received government approval to generic in India, with the rollout expected in March. Semaglutide is widely used for the treatment of Type 2 Semaglutide launch overview

Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V

Lujambio, L

Retatrutide has a long half-life estimated at approximately six days based on phase 2 pharmacokinetic data (Jastreboff et al., NEJM 2023) meaning that drug levels rise gradually and remain relatively stable between weekly doses once a steady state is achieved (typically after approximately four to five half-lives, or around four to five weeks of weekly dosing)

At JoinHub Pharma, we position ourselves as a trusted injection manufacturer, supplier, and exporter for Semaglutide, committed to delivering quality-driven formulations from India to global markets